Zhou C, Gan L, Zhang Y, Zhang F, Wang G, Jin L
Sci China B Chem. 2024; 52(4):415-458.
PMID: 38624300
PMC: 7089408.
DOI: 10.1007/s11426-009-0103-2.
Navas F, Chocarro-Calvo A, Iglesias-Hernandez P, Fernandez-Garcia P, Morales V, Garcia-Martinez J
J Med Chem. 2024; 67(8):6410-6424.
PMID: 38592014
PMC: 11056991.
DOI: 10.1021/acs.jmedchem.3c02393.
Marotta C, Cirri D, Kanavos I, Ronga L, Lobinski R, Funaioli T
Pharmaceutics. 2024; 16(2).
PMID: 38399332
PMC: 10892879.
DOI: 10.3390/pharmaceutics16020278.
Aputen A, Elias M, Gilbert J, Sakoff J, Gordon C, Scott K
Int J Mol Sci. 2024; 25(4).
PMID: 38396859
PMC: 10888562.
DOI: 10.3390/ijms25042181.
Mancera-Ortiz I, Chen J, Slade T, Yao X, Zhang S, Day C
Bioconjug Chem. 2023; 34(10):1873-1881.
PMID: 37813818
PMC: 11740447.
DOI: 10.1021/acs.bioconjchem.3c00368.
Pyrenebutyrate Pt(IV) Complexes with Nanomolar Anticancer Activity.
Ahmedova A, Mihaylova R, Stoykova S, Mihaylova V, Burdzhiev N, Elincheva V
Pharmaceutics. 2023; 15(9).
PMID: 37765279
PMC: 10537052.
DOI: 10.3390/pharmaceutics15092310.
Platinum(IV) compounds as potential drugs: a quantitative structure-activity relationship study.
Novak J, Zykova A, Potemkin V, Sharutin V, Sharutina O
Bioimpacts. 2023; 13(5):373-382.
PMID: 37736338
PMC: 10509740.
DOI: 10.34172/bi.2023.24180.
Oxidation of the Platinum(II) Anticancer Agent [Pt{(-BrCF)NCHCHNEt}Cl(py)] to Platinum(IV) Complexes by Hydrogen Peroxide.
Ojha R, Junk P, Bond A, Deacon G
Molecules. 2023; 28(17).
PMID: 37687231
PMC: 10490441.
DOI: 10.3390/molecules28176402.
Quaternary Ammonium Palmitoyl Glycol Chitosan (GCPQ) Loaded with Platinum-Based Anticancer Agents-A Novel Polymer Formulation for Anticancer Therapy.
Lerchbammer-Kreith Y, Hejl M, Sommerfeld N, Weng-Jiang X, Odunze U, Mellor R
Pharmaceuticals (Basel). 2023; 16(7).
PMID: 37513938
PMC: 10386324.
DOI: 10.3390/ph16071027.
Platinum(IV) Derivatives of [Pt(1,2-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)] with Diclofenac Ligands in the Axial Positions: A New Class of Potent Multi-action Agents Exhibiting Selectivity to Cancer Cells.
Kostrhunova H, McGhie B, Markova L, Novakova O, Kasparkova J, Aldrich-Wright J
J Med Chem. 2023; 66(12):7894-7908.
PMID: 37285472
PMC: 10291556.
DOI: 10.1021/acs.jmedchem.3c00269.
Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents.
Aputen A, Elias M, Gilbert J, Sakoff J, Gordon C, Scott K
Cancers (Basel). 2023; 15(9).
PMID: 37173934
PMC: 10177380.
DOI: 10.3390/cancers15092460.
The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CHCOO)Cl(NH)(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake.
Gabano E, Zanellato I, Pinton G, Moro L, Ravera M, Osella D
Bioinorg Chem Appl. 2023; 2022:3698391.
PMID: 36620349
PMC: 9822769.
DOI: 10.1155/2022/3698391.
Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments.
Giorgi E, Binacchi F, Marotta C, Cirri D, Gabbiani C, Pratesi A
Molecules. 2023; 28(1).
PMID: 36615466
PMC: 9822110.
DOI: 10.3390/molecules28010273.
Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells.
Khoury A, Sakoff J, Gilbert J, Karan S, Gordon C, Aldrich-Wright J
Pharmaceutics. 2022; 14(12).
PMID: 36559273
PMC: 9853328.
DOI: 10.3390/pharmaceutics14122780.
Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs.
Spector D, Pavlov K, Beloglazkina E, Krasnovskaya O
Int J Mol Sci. 2022; 23(23).
PMID: 36498837
PMC: 9739791.
DOI: 10.3390/ijms232314511.
Advances in the Development of Prodrugs as Selective Modulators of Estrogen Receptors.
Pollock J, Parker H
J Endocr Soc. 2022; 6(12):bvac158.
PMID: 36381014
PMC: 9646968.
DOI: 10.1210/jendso/bvac158.
Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy.
Zhang C, Kang T, Wang X, Song J, Zhang J, Li G
Front Pharmacol. 2022; 13:1035217.
PMID: 36324675
PMC: 9618881.
DOI: 10.3389/fphar.2022.1035217.
Platinum(IV) Complexes of the 1,3,5-Triamino Analogue of the Biomolecule Cis-Inositol Designed as Innovative Antineoplastic Drug Candidates.
Velcheva V, Hegetschweiler K, Momekov G, Ivanova S, Ugrinov A, Morgenstern B
Pharmaceutics. 2022; 14(10).
PMID: 36297500
PMC: 9611922.
DOI: 10.3390/pharmaceutics14102057.
Targeting of the intracellular redox balance by metal complexes towards anticancer therapy.
Murillo M, Gaiddon C, Lagadec R
Front Chem. 2022; 10:967337.
PMID: 36034648
PMC: 9405673.
DOI: 10.3389/fchem.2022.967337.
Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration.
Barbanente A, Gandin V, Ceresa C, Marzano C, Ditaranto N, Hoeschele J
Int J Mol Sci. 2022; 23(13).
PMID: 35806087
PMC: 9266928.
DOI: 10.3390/ijms23137081.
